Evidence map›Paper›PMID 42236533›Full record

ArticleScientific reports2026

MAPK pathway inhibitors enhance radioiodine sensitivity in anaplastic thyroid carcinoma through promoting NIS expression and ARF4-mediated NIS membrane transport.

Junfang Wang, Zhenzhen Zeng, Shasha Xu, Xiaoxian Wang, Keliu Wu, Yongguang Chang, Guanzheng Wang, Baoping Liu, Ruihua Wang, Xingmin Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Junfang WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Zhenzhen ZengDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Shasha XuDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Xiaoxian WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Keliu WuDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Yongguang ChangDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Guanzheng WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Baoping LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China.
Ruihua WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China. wangruihua2004@126.com.
Xingmin HanDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 Longhu Zhonghuan Road Jinshui District, Zhengzhou City, 450000, Henan Province, China. xmhan@zzu.edu.cn.

Funding

Henan Science and Technology Research Project 242102311089National Natural Science Foundation of China 82171983
6 · The paper itself

Abstract

Anaplastic thyroid cancer (ATC) patient develops resistance to radioactive iodine (RAI) due to diminished sodium-iodide symporter (NIS) expression and mislocalization to the cell membrane. MAPK pathway inhibitors have demonstrated efficacy in enhancing RAI avidity in radioiodine-refractory papillary thyroid carcinoma and ATC. Elucidating this mechanism may lead to novel therapeutic approaches for ATC treatment. The cytotoxic effects of three MAPK pathway inhibitors (selumetinib, vemurafenib, dabrafenib) were assessed in ATC cell lines and xenograft models via viability assays and

Indexed as

Iodine RadioisotopesMAP Kinase Signaling SystemProtein Kinase InhibitorsSymportersThyroid Carcinoma, AnaplasticThyroid NeoplasmsAnimalsCell Line, TumorCell MembraneGene Expression Regulation, NeoplasticHumansMiceSodium-Iodide SymportersXenograft Model Antitumor AssaysIodine RadioisotopesProtein Kinase InhibitorsSodium-Iodide SymportersSymporters

Identifiers

PMID42236533
PMCPMC13473092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.